Maynard Um
-
-
-
-
-
-
-
UBS Starts Zealand Pharma A/S (ZEAL:DC) (ZEAL) at Buy
-
-
-
-
-
-
-
Morgan Stanley Upgrades Zealand Pharma A/S (ZEAL:DC) (ZEAL) to Overweight
-
-
-
-
-
-
-
Zealand Pharma (ZEAL) announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
-
-
-
-
396,408 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

